Literature DB >> 23318792

Daptomycin versus vancomycin in treatment of methicillin-resistant Staphylococcus aureus meningitis in an experimental rabbit model.

Selin Bardak-Ozcem1, Tuncer Turhan, Oguz Resat Sipahi, Bilgin Arda, Husnu Pullukcu, Tansu Yamazhan, Meltem Isikgoz-Tasbakan, Hilal Sipahi, Sercan Ulusoy.   

Abstract

In this study, we aimed to compare the antibacterial activities of daptomycin and vancomycin in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) meningitis (induced by MRSA strain ATCC 43300) in an experimental rabbit meningitis model. After an 8-h period of treatment, bacterial counts decreased significantly in both treatment groups compared to the control group (P < 0.05). However, there was no statistically significant difference between treatment groups. Our results suggest that the antibacterial activity of daptomycin is similar to vancomycin for treatment in the experimental MRSA meningitis model in rabbits.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23318792      PMCID： PMC3591926          DOI： 10.1128/AAC.01996-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  Evaluation of ceftobiprole activity against a variety of gram-negative pathogens, including Escherichia coli, Haemophilus influenzae (β-lactamase positive and β-lactamase negative), and Klebsiella pneumoniae, in a rabbit meningitis model.

Authors:  A Stucki; M Cottagnoud; F Acosta; U Egerman; J Läuffer; P Cottagnoud
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

2.  Practice guidelines for the management of bacterial meningitis.

Authors:  Allan R Tunkel; Barry J Hartman; Sheldon L Kaplan; Bruce A Kaufman; Karen L Roos; W Michael Scheld; Richard J Whitley
Journal:  Clin Infect Dis       Date:  2004-10-06       Impact factor: 9.079

3.  Linezolid in the treatment of methicillin-resistant staphylococcal post-neurosurgical meningitis: a series of 17 cases.

Authors:  Oguz Resat Sipahi; Selin Bardak; Tuncer Turhan; Bilgin Arda; Husnu Pullukcu; Mete Ruksen; Sohret Aydemir; Tayfun Dalbasti; Taskin Yurtseven; Mehmet Zileli; Sercan Ulusoy
Journal:  Scand J Infect Dis       Date:  2011-06-15

4.  Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis.

Authors:  Peter Gerber; Armin Stucki; Fernando Acosta; Marianne Cottagnoud; Philippe Cottagnoud
Journal:  J Antimicrob Chemother       Date:  2006-02-03       Impact factor: 5.790

5.  Vancomycin versus teicoplanin in the therapy of experimental methicillin-resistant Staphylococcus aureus (MRSA) meningitis.

Authors:  Oguz Resat Sipahi; Bilgin Arda; Taskin Yurtseven; Hilal Sipahi; Erkin Ozgiray; Bedia Mutay Suntur; Sercan Ulusoy
Journal:  Int J Antimicrob Agents       Date:  2005-10-10       Impact factor: 5.283

6.  Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis.

Authors:  Philippe Cottagnoud; Marc Pfister; Fernando Acosta; Marianne Cottagnoud; Lukas Flatz; Felix Kühn; Hans-Peter Müller; Armin Stucki
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

7.  Daptomycin in experimental murine pneumococcal meningitis.

Authors:  Barry B Mook-Kanamori; Mark S Rouse; Cheol-In Kang; Diederik van de Beek; James M Steckelberg; Robin Patel
Journal:  BMC Infect Dis       Date:  2009-04-30       Impact factor: 3.090
  7 in total
  2 in total

1.  Bacterial meningitis in older adults.

Authors:  Diedre Hofinger; Larry E Davis
Journal:  Curr Treat Options Neurol       Date:  2013-08       Impact factor: 3.598

2.  Mass spectrometric identification of phenol-soluble modulins in the ATCC® 43300 standard strain of methicillin-resistant Staphylococcus aureus harboring two distinct phenotypes.

Authors:  K S Jang; M Park; J Y Lee; J S Kim
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-01-14       Impact factor: 3.267
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.